Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus GIAZO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus GIAZO.
CORTIFOAM vs GIAZO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Balsalazide is a prodrug that is converted by colonic bacteria into mesalamine (5-aminosalicylic acid), which inhibits prostaglandin and leukotriene production, reducing colonic inflammation.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
Adults: 2 tablets (1.2 g) orally three times daily (3.6 g/day) for up to 6 weeks.
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Terminal elimination half-life approximately 0.5-1.0 hour for 5-ASA (active); metabolite half-life ~5-10 hours. Clinical context: short half-life necessitates multi-matrix release formulation for once-daily dosing in ulcerative colitis.
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Primarily metabolized in the gut mucosa and liver to N-acetyl-5-aminosalicylic acid. Renal excretion of acetylated metabolite accounts for ~25-30% of dose; fecal excretion of parent drug and metabolite ~50-60%. Biliary excretion minimal.
Category C
Category C
Corticosteroid
Corticosteroid